Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 25.13 is 256% above its 5-year average of 7.05, near the low end of its 5-year range (0.04–90.01).
As of the fiscal period ended Tuesday, June 30, 2026. 169.32% above its 12-month average of 9.33.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 25.13.
QUICK RATIO (ACID-TEST)
25.13
QUICK RATIO (ACID-TEST) AVG TTM
9.33
QUICK RATIO (ACID-TEST) AVG 3Y
5.14
QUICK RATIO (ACID-TEST) AVG 5Y
7.05
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+169.32%
CURRENT VS 3Y AVG
+389.32%
CURRENT VS 5Y AVG
+256.41%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
2.99
median of 635 covered companies
CURRENT VS SECTOR MEDIAN
+740.61%
vs the sector median at left
Immix Biopharma, Inc.
Market Cap
$538.51M
Quick Ratio (Acid-Test)
25.13
TTM Avg
9.33
3Y Avg
5.14
5Y Avg
7.05
Market Cap
$537.47M
Quick Ratio (Acid-Test)
8.95
TTM Avg
10.43
3Y Avg
5.97
5Y Avg
5.34
Market Cap
$537.29M
Quick Ratio (Acid-Test)
9.66
TTM Avg
5.09
3Y Avg
5.58
5Y Avg
6.85
Market Cap
$550.03M
Quick Ratio (Acid-Test)
1.68
TTM Avg
2.23
3Y Avg
2.63
5Y Avg
2.59
Market Cap
$521.19M
Quick Ratio (Acid-Test)
26.78
TTM Avg
15.83
3Y Avg
15.06
5Y Avg
15.09
Market Cap
$514.49M
Quick Ratio (Acid-Test)
33.56
TTM Avg
31.41
3Y Avg
17.80
5Y Avg
16.41
Market Cap
$552.54M
Quick Ratio (Acid-Test)
5.42
TTM Avg
12.18
3Y Avg
12.18
5Y Avg
12.18
Market Cap
$514.07M
Quick Ratio (Acid-Test)
2.38
TTM Avg
3.66
3Y Avg
6.23
5Y Avg
9.46
Market Cap
$561.45M
Quick Ratio (Acid-Test)
3.46
TTM Avg
4.63
3Y Avg
6.00
5Y Avg
6.13
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | $538.51M | 25.13 | 9.33 | 5.14 | 7.05 |
| Delcath Systems, Inc. (DCTH)vs › | $537.47M | 8.95 | 10.43 | 5.97 | 5.34 |
| Crescent Biopharma, Inc. (CBIO)vs › | $537.29M | 9.66 | 5.09 | 5.58 | 6.85 |
| Nuvectis Pharma, Inc. (NVCT)vs › | $550.03M | 1.68 | 2.23 | 2.63 | 2.59 |
| Altimmune, Inc. (ALT)vs › | $521.19M | 26.78 | 15.83 | 15.06 | 15.09 |
| Monopar Therapeutics Inc. (MNPR)vs › | $514.49M | 33.56 | 31.41 | 17.80 | 16.41 |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $552.54M | 5.42 | 12.18 | 12.18 | 12.18 |
| 908 Devices Inc. (MASS)vs › | $514.07M | 2.38 | 3.66 | 6.23 | 9.46 |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $561.45M | 3.46 | 4.63 | 6.00 | 6.13 |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
Quick Ratio
25.13
Excludes inventory
Current Ratio
25.13
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 25.13 |
| 2026-03-31 | 8.76 |
| 2025-12-31 | 10.01 |
| 2025-09-30 | 1.53 |
| 2025-06-30 | 1.23 |
| 2025-03-31 | 1.80 |
| 2024-12-31 | 2.33 |
| 2024-09-30 | 3.47 |
| 2024-06-30 | 7.00 |
| 2024-03-31 | 5.82 |
| 2023-12-31 | 5.32 |
| 2023-09-30 | 7.90 |
| 2023-06-30 | 6.47 |
| 2023-03-31 | 8.85 |
| 2022-12-31 | 11.70 |
| 2022-09-30 | 26.90 |
| 2022-06-30 | 19.53 |
| 2022-03-31 | 54.82 |
| 2021-12-31 | 90.01 |
| 2021-09-30 | 0.04 |
| 2021-06-30 | 0.05 |
| 2021-03-31 | 0.00 |
| 2020-12-31 | 0.10 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
